Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Positron emission tomography (PET): expanding the horizons of oncology drug development.

Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr, Kuhn JG.

Invest New Drugs. 2003 Aug;21(3):309-40. Review.

PMID:
14578681
[PubMed - indexed for MEDLINE]
2.

The role of positron emission tomography in pharmacokinetic analysis.

Fischman AJ, Alpert NM, Babich JW, Rubin RH.

Drug Metab Rev. 1997 Nov;29(4):923-56. Review.

PMID:
9421680
[PubMed - indexed for MEDLINE]
3.

Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.

Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, Matthews JC, Denny WA, Baguley BC, Jones T, Price PM.

Cancer Res. 1997 Jun 1;57(11):2172-80.

PMID:
9187117
[PubMed - indexed for MEDLINE]
Free Article
4.

PET for in vivo pharmacokinetic and pharmacodynamic measurements.

Gupta N, Price PM, Aboagye EO.

Eur J Cancer. 2002 Nov;38(16):2094-107. Review.

PMID:
12387835
[PubMed - indexed for MEDLINE]
5.

Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.

Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, Myers R, Gamage SA, Denny WA, Baguley BC, Price PM.

Cancer Res. 2001 Apr 1;61(7):2935-44.

PMID:
11306471
[PubMed - indexed for MEDLINE]
Free Article
6.

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee.

J Natl Cancer Inst. 2006 May 3;98(9):580-98. Review.

PMID:
16670384
[PubMed - indexed for MEDLINE]
Free Article
7.

Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.

Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, Price PM.

Curr Pharm Des. 2001 Dec;7(18):1863-92. Review.

PMID:
11772355
[PubMed - indexed for MEDLINE]
8.

The use of imaging in preclinical drug development.

Vanderheyden JL.

Q J Nucl Med Mol Imaging. 2009 Aug;53(4):374-81.

PMID:
19834446
[PubMed - indexed for MEDLINE]
Free Article
9.

(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

Vallabhajosula S.

Semin Nucl Med. 2007 Nov;37(6):400-19. Review.

PMID:
17920348
[PubMed - indexed for MEDLINE]
10.

What does positron emission tomography offer oncology?

Anderson H, Price P.

Eur J Cancer. 2000 Oct;36(16):2028-35. Review.

PMID:
11044638
[PubMed - indexed for MEDLINE]
11.

The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.

Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL.

Cancer Res. 2002 Oct 15;62(20):5912-9.

PMID:
12384557
[PubMed - indexed for MEDLINE]
Free Article
12.

Fundamentals of positron emission tomography and applications in preclinical drug development.

Cherry SR.

J Clin Pharmacol. 2001 May;41(5):482-91. Review.

PMID:
11361044
[PubMed - indexed for MEDLINE]
13.

Autoradiography with positron emitting isotopes in positron emission tomography tracer discovery.

Bergström M, Awad R, Estrada S, Mälman J, Lu L, Lendvai G, Bergström-Pettermann E, Långström B.

Mol Imaging Biol. 2003 Nov-Dec;5(6):390-6.

PMID:
14667493
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Fischman AJ, Alpert NM, Rubin RH.

Clin Pharmacokinet. 2002;41(8):581-602. Review.

PMID:
12102642
[PubMed - indexed for MEDLINE]
15.

Clinical molecular imaging with positron emission tomography.

Saleem A, Charnley N, Price P.

Eur J Cancer. 2006 Aug;42(12):1720-7. Epub 2006 Jun 22. Review.

PMID:
16797972
[PubMed - indexed for MEDLINE]
16.

Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.

Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL.

Cancer Res. 2003 Oct 1;63(19):6252-7.

PMID:
14559811
[PubMed - indexed for MEDLINE]
Free Article
17.

Positron Emission Tomography: applications in drug discovery and drug development.

Wang J, Maurer L.

Curr Top Med Chem. 2005;5(11):1053-75. Review.

PMID:
16181131
[PubMed - indexed for MEDLINE]
18.

Trends in nucleoside tracers for PET imaging of cell proliferation.

Toyohara J, Fujibayashi Y.

Nucl Med Biol. 2003 Oct;30(7):681-5. Review. No abstract available.

PMID:
14499325
[PubMed - indexed for MEDLINE]
19.

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Bergström M, Grahnén A, Långström B.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66. Epub 2003 Aug 22. Review.

PMID:
12937873
[PubMed - indexed for MEDLINE]
20.

Positron emitting tracers in pre-clinical drug development.

Fernandes E, Barbosa Z, Clemente G, Alves F, Abrunhosa AJ.

Curr Radiopharm. 2012 Apr;5(2):90-8. Review.

PMID:
22280107
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk